Abstract
Landmark molecular profiling efforts have identified multiple targetable alterations in cholangiocarcinoma. Among the molecular-driven subsets of cholangiocarcinoma, targeting the fi-broblast growth factor receptor (FGFR) has shown promise and represents the first targeted therapy to be approved in treatment-refractory, advanced cholangiocarcinoma. In this review, we provide an up-to-date overview of the clinical development of FGFR inhibitors in advanced cholangiocarci-noma. We review the FGFR pathway and discuss emerging issues including resistance to FGFR inhibitors. We end with a discussion on future considerations to optimize the potential of this class of therapeutics in advanced cholangiocarcinoma.
Original language | English (US) |
---|---|
Article number | 1706 |
Journal | Cancers |
Volume | 13 |
Issue number | 7 |
DOIs | |
State | Published - Apr 1 2021 |
Externally published | Yes |
Keywords
- Cholangiocarcinoma
- Debio 1347
- Derazantinib
- Erdafitinib
- Fibroblast growth factor receptor (FGFR)
- Futibatinib
- Infigratinib
- Pemigatinib
- TAS-120
ASJC Scopus subject areas
- Oncology
- Cancer Research